Pharmicell Co.,Ltd. Logo

Pharmicell Co.,Ltd.

Biopharma firm in stem cell therapies, biochemicals, cell banking, and stem cell cosmetics.

005690 | KO

Overview

Corporate Details

ISIN(s):
KR7005690003
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 874 (신사동, 쌍봉빌딩 7층), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology. The company is a pioneer in the field, having developed and commercialized Hearticellgram®-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its business is diversified across four main segments: stem cell therapeutics, including ongoing research for conditions like liver disease; a biochemical division that conducts oligonucleotide synthesis and produces nucleosides, mPEGs, and pharmaceutical intermediates; a stem cell banking business for adult and cord blood ('Twelve' brand); and a line of cosmetics derived from stem cell culture media ('By Pharmicell lab' brand).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.0 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 779.0 KB
2025-07-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 110.2 KB
2025-07-08 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-05-08 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 785.5 KB
2025-04-30 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-04-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-30 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 32.6 KB
2025-04-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 111.8 KB
2025-04-22 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-04-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 118.0 KB
2025-04-01 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 32.6 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.9 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Pharmicell Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharmicell Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharmicell Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.